共 16 条
D-peptide hydrogels as a long-acting multipurpose drug delivery platform for combined contraception and HIV prevention
被引:1
|作者:
Pentlavalli, Sreekanth
[1
]
Coulter, Sophie M.
[1
]
An, Yuming
[1
]
Cross, Emily R.
[1
]
Sun, Han
[1
]
Moore, Jessica, V
[1
]
Bin Sabri, Akmal
[1
]
Greer, Brett
[2
]
Vora, Lalitkumar
[1
]
Mccarthy, Helen O.
[1
]
Laverty, Garry
[1
]
机构:
[1] Queens Univ Belfast, Med Biol Ctr, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, North Ireland
[2] Sch Biol Sci, Biol Sci Bldg, 19 Chlorine Gardens, Belfast BT9 5DL, North Ireland
基金:
英国工程与自然科学研究理事会;
英国惠康基金;
关键词:
Long-acting injectable;
Peptide hydrogel;
Sustained release;
HIV/AIDS;
Contraception;
Enzyme instructed self-assembly;
Multipurpose prevention technologies;
MICROARRAY PATCHES;
IN-VITRO;
CABOTEGRAVIR;
MICRONEEDLES;
DEGRADATION;
DESIGN;
WOMEN;
ACIDS;
D O I:
10.1016/j.jconrel.2024.12.052
中图分类号:
O6 [化学];
学科分类号:
0703 ;
摘要:
New multipurpose prevention technology products for use by women, focused on reducing HIV infection and preventing unwanted pregnancies, are a global health priority. Discreet long-acting formulations will empower women with greater choice around their sexual health. This paper outlines the development of a long-acting technology that enables multiple drugs to be incorporated within one injectable platform. This fixed-dose combination product is formed from a phosphorylated D-peptide (naphthalene-2-ly)-acetyl-diphenylalaninelysine-tyrosine-glycine-OH (Napffky(p)G-OH) that enables the highly hydrophobic drugs MIV-150 (HIV antiretroviral) and etonogestrel (contraceptive) to be solubilized together within aqueous solvents. Upon subcutaneous injection, this D-peptide-drug combination self-assembles in response to phosphatase enzymes present within the skin space to form an in situ forming drug-releasing hydrogel depot. Oscillatory rheology confirmed the formation of hydrogels, which began within 10 s exposure to 3.98 U/mL phosphatase enzymes and continued for 198 mins for a Napffk(MIV-150)y(p)G-OH + Napffk(ENG)y(p)G-OH combination (8:2 ratio). Biostability against proteases, an important consideration for long-acting injectables, was demonstrated for at least 28 days in vitro. Covalent attachment of each drug to the D-peptide via an ester linkage enabled sustained release of the drug in an unmodified form via hydrolysis of the D-peptide-drug linker. This significantly reduced the initial drug burst. Low toxicity was also demonstrated in vitro via cell culture (MTS, LHS, Live/Dead (R)) and within in vivo studies (H&E staining). The fixed dose combination was able to deliver clinically relevant concentrations of each drug to Sprague-Dawley rats for at least 49 days, providing proof-of-concept for the use of hydrogel-forming D-peptides (Napffky(p)G-OH) as a long-acting injectable platform for the delivery of multiple hydrophobic drugs.
引用
收藏
页码:30 / 44
页数:15
相关论文